The favorable toxicology results de-risk the NMRA-215 program and support the IND timeline. Traders should monitor for the IND submission in Q4 2026 and subsequent Phase 1 initiation, which could drive further upside if clinical data is positive. Given the company's small market cap (~$276M), positive pipeline news may have outsized impact.
Price Chart
Executive Summary
Neumora Therapeutics reported favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor in development for obesity and cardiometabolic disease. A repeat 13-week rat study found no unexpected adverse findings, clearing a key safety concern and enabling the company to plan an IND submission in Q4 2026 with a Phase 1 study by end of 2026. This removes a significant pipeline risk and supports advancement toward the clinic.
Key Facts
- Repeat 13-week rat toxicology study (162 animals) showed no unexpected in-life adverse findings, resolving concerns from a prior study where 5 of 142 animals had adverse events.
- Company opened a for-cause audit of the prior study, which revealed discrepancies; management believes prior findings were not related to NMRA-215.
- Plans to submit an IND for NMRA-215 in Q4 2026 and initiate a Phase 1 study by the end of 2026.
- NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor targeting obesity and cardiometabolic disease with pre-clinical data showing class-leading weight loss and additive effects with semaglutide.
Financial Impact
No financial data provided; the event is a pre-clinical pipeline milestone with no revenue impact. Positive catalyst for stock valuation but no direct financial figures.
Risk Factors
- Pre-clinical data may not translate to clinical success; NMRA-215 still faces Phase 1 safety and efficacy hurdles.
- Competition from other NLRP3 inhibitors and obesity treatments (e.g., incretins) could limit commercial potential.
- Company is pre-revenue with no financial data provided; cash runway and need for future financing are not addressed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-316819 |
| Document: nmra-ex99_1.htm | 0001193125-26-316819 |
| Document: 0001193125-26-316819-index-headers.html | 0001193125-26-316819 |
| Document: 0001193125-26-316819-index.html | 0001193125-26-316819 |
| Document: 0001193125-26-316819.txt | 0001193125-26-316819 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | 144 | $1.63 $0.6918 | ▲ +57.56% | ▲ +57.03% | $0.4999 (+69.33%) |
Aug 17, 2026 6w ago | 144 | $1.64 $0.7732 | ▲ +52.85% | ▲ +51.54% | $0.4999 (+69.52%) |
Aug 14, 2026 7w ago | 8-K | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Aug 14, 2026 7w ago | Press Release | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Jul 27, 2026 9w ago | 8-K | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jul 27, 2026 9w ago | Press Release | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jun 15, 2026 15w ago | 8-K | $0.9145 $1.60 | ▼ −74.96% | ▼ −75.71% | $0.4999 (+45.34%) |
Apr 17, 2026 24w ago | DEFA14A | $2.19 $1.77 | ▼ −19.18% | ▼ −23.38% | $0.4999 (−77.17%) |
Mar 30, 2026 26w ago | Press Release | $1.93 $2.25 | ▲ +16.58% | ▲ +3.98% | $0.4999 (−74.10%) |
Mar 16, 2026 28w ago | Press Release | $2.87 $2.03 | ▼ −29.27% | ▼ −33.05% | $0.4999 (−82.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access